Sera Prognostics appoints Dr. Jane F. Barlow to Board of Directors

SERA PROGNOSTICS, INC.

Dr. Jane F. Barlow appointed as Class I Director effective April 11, 2022; term expires at 2022 annual meeting.
Dr. Barlow brings experience from CVS Health, Medco, and boards of ContraFect, Viracta, Point Health.
Granted non-qualified stock option with $240,000 grant date fair value, vesting monthly over 36 months.
Entitled to annual cash retainer of $35,000 for non-employee director service, prorated.
Company entered into standard indemnification agreement with Dr. Barlow.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jane F. Barlow

Class I Director

SERA · SERA PROGNOSTICS, INC.

Effective: 2022-04-11
Filed: April 12, 2022, 7:59 PM ET

On April 11, 2022, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Jane F. Barlow, M.D., MPH, MBA, effective April 11, 2022 (the “Effective Date”), as a director to the Board to serve as a Class I Director with a term expiring at the Company’s 2022 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jane F. Barlow was appointed as Class I Director at SERA PROGNOSTICS, INC..

Action: appointed
Role: Class I Director

Exact text from the filing

On April 11, 2022, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Jane F. Barlow, M.D., MPH, MBA, effective April 11, 2022 (the “Effective Date”), as a director to the Board to serve as a Class I Director with a term expiring at the Company’s 2022 annual meeting of stockholders.

View on SEC.gov

SERA PROGNOSTICS, INC. filing history →

Source: SEC EDGAR

accession 0001534969-22-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.